138 related articles for article (PubMed ID: 38087715)
1. A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease.
Fatoum H; Zeiser R; Hashmi SK
Blood Rev; 2024 Jan; 63():101142. PubMed ID: 38087715
[TBL] [Abstract][Full Text] [Related]
2. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.
DeFilipp Z; Kim HT; Yang Z; Noonan J; Blazar BR; Lee SJ; Pavletic SZ; Cutler C
Blood Adv; 2022 Dec; 6(24):6263-6270. PubMed ID: 36083121
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
4. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rituximab in steroid-refractory chronic graft-versus-host disease.
Colunga-Pedraza PR; Barbosa-Castillo LM; Coronado-Alejandro EU; Vaquera-Alfaro HA; López-Reyna IG; Colunga-Pedraza JE; Gómez-Almaguer D
Transpl Immunol; 2023 Dec; 81():101959. PubMed ID: 37972876
[TBL] [Abstract][Full Text] [Related]
7. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
Cazeau N; Rodriguez S
Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY; Zhao P; Zhang Y; Wang JS
PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
Front Immunol; 2022; 13():954268. PubMed ID: 35990629
[TBL] [Abstract][Full Text] [Related]
11. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
[TBL] [Abstract][Full Text] [Related]
12. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH
Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214
[TBL] [Abstract][Full Text] [Related]
13. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
Elad S; Levitt M; M Y S
Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
[TBL] [Abstract][Full Text] [Related]
14. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Mohseni R; Mahdavi Sharif P; Behfar M; Modaresi MR; Shirzadi R; Mardani M; Jafari L; Jafari F; Nikfetrat Z; Hamidieh AA
Stem Cell Res Ther; 2023 Sep; 14(1):256. PubMed ID: 37726865
[TBL] [Abstract][Full Text] [Related]
16. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Axt L; Naumann A; Toennies J; Haen SP; Vogel W; Schneidawind D; Wirths S; Moehle R; Faul C; Kanz L; Axt S; Bethge WA
Bone Marrow Transplant; 2019 Nov; 54(11):1805-1814. PubMed ID: 31089279
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
[TBL] [Abstract][Full Text] [Related]
18. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
Kim SS
Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
[TBL] [Abstract][Full Text] [Related]
19. Chronic graft-versus-host disease presenting as eosinophilic fasciitis: therapeutic challenges and an additional case.
Ganta CC; Chatterjee S; Pohlman B; Hojjati M
J Clin Rheumatol; 2015 Mar; 21(2):86-94. PubMed ID: 25710860
[TBL] [Abstract][Full Text] [Related]
20. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]